Insider buying last 90 days
No open-market insider purchases were filed for VRTX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every VRTX insider filing, plotted on the chart in Gekko.Open VRTX in Gekko
NASDAQ: VRTX
Vertex Pharmaceuticals (VRTX) Stock Analysis & Forecast
$508.34−8.00 (−1.5%)
Close on Sep 18, 2026. Page updated Sep 19, 9:18 pm ET.
Gekko Brief
AI summaryVertex Pharmaceuticals closes at $508.34, down 1.5% on the session, sitting just under its 50-day average of $510.60 and above its 200-day average of $470.15. The GekkoIndex reads 65.5, placing the stock in the Accumulation zone, while price stands 9.7% above Gekko Fair Value of $463.32. Over the past year the stock has returned 31.3%, though the past month shows a 7.9% decline.
This week's coverage centers on Vertex's raised full-year 2026 revenue guidance, now set between $13.1 billion and $13.2 billion, following Q2 2026 revenue of $3.33 billion and diluted EPS of $4.31, with shares up 13% year to date noted in that report. Pipeline updates from the CEO's appearance at a healthcare conference point to expanding focus areas including renal medicine, rare endocrine assets, and cell therapies, alongside a BLA acceptance for Pove in IgAN with a PDUFA date and continued CASGEVY label expansion. A marketing partnership tied to the non-opioid pain treatment Journavx also drew attention this week.
The next earnings date falls on 2 November 2026, 43 days out and beyond a typical 20-day holding window; the prior print on 3 August 2026 showed EPS of $4.20 against a $4.15 estimate with a 0.3% reaction, part of a stretch of 5 beats in the last 8 quarters where average absolute moves post-earnings run 5.8%. Seasonality over the next 20 trading days has averaged 3.5% across 5 years, positive in 4 of them. Analyst coverage from 26 firms includes 21 buy ratings, with a consensus target of $569.19, reflecting 12% upside from current levels.
Written by AI and checked automatically against the figures on this page. Generated Sep 20, 2026 from the data above.
Price vs fair value
Close $508.34200-day averageGekko Fair Value $463.32
Key stats
- Market cap
- $129.0B
- P/E ratio
- 29.9
- Forward P/E
- 24
- EPS, TTM
- $17.30
- Revenue, TTM
- $12.59B
- Profit margin
- 35%
- Dividend yield
- —
- Beta
- 0.32
- Volume
- 2.42M avg 969,865
- 1-year return
- +31.3%
- Typical daily move
- ±2.2%
- Typical 20-day move
- ±4.4%
- 50-day average
- $510.60
- 200-day average
- $470.15
- Next earnings
- Nov 2 after close
- Shares outstanding
- 253.3M
Vertex Pharmaceuticals swing-trade checklist
Vertex Pharmaceuticals scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $508.34 sits between the 50-day ($510.60) and 200-day ($470.15) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
65.5, Accumulation
Reading 65.5 is in the Accumulation zone.
See the GekkoIndex - Fair valueheadwind
9.7% above
Price is 9.7% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 43 days
Next report Nov 2, 2026, 43 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+3.5% on average
From this point in the calendar, the next 20 trading days averaged +3.5% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Vertex Pharmaceuticals stock chart and price history
Vertex Pharmaceuticals closed at $508.34 on Sep 18, 2026, +31.3% over the past year, inside a 52-week range of $374.17 to $560.25.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −7.9%
- 3 months
- +12.6%
- 6 months
- +11.0%
- 1 year
- +31.3%
The full VRTX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open VRTX in Gekko
Follow Vertex Pharmaceuticals through every session
Put VRTX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track VRTX in GekkoFree for 7 days. No credit card required.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals makes medicines aimed at cystic fibrosis, a disease tied to mutations in the CFTR gene. Its lineup of cleared drugs, among them SYMDEKO/SYMKEVI, ORKAMBI, KALYDECO and TRIKAFTA, is built around correcting the effects of particular gene defects, and TRIKAFTA is meant for CF patients six years old or older who carry the F508del mutation on at least one allele. This CF-focused portfolio is the foundation the company has built its name on.
Past its established CF business, Vertex runs a wide set of experimental programs at different clinical stages, touching on alpha-1 antitrypsin deficiency, a kidney disorder called APOL1-mediated FSGS, Type 1 diabetes, several categories of pain, and severe sickle cell disease together with transfusion-dependent beta-thalassemia. In the US its drugs move to patients via specialty pharmacies and distribution partners, while sales abroad run through distributors, retail pharmacy chains, hospitals and clinics. The company also pairs with outside research partners, including CRISPR Therapeutics, Moderna, Kymera Therapeutics and Merck KGaA, among others.
Vertex traces back to 1989 and operates out of Boston, Massachusetts. Its stock is listed on the NASDAQ under the ticker VRTX.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- vrtx.com
Vertex Pharmaceuticals GekkoIndex: the smart money zone
Vertex Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 65.5, in the Accumulation zone, up 3.3 points over five sessions.
65.5Accumulation
Up 3.3 points over five sessions.
Reading for Sep 18, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 21 | +1.4% | +5.7% | ||
| Accumulation (current zone) | 215 | +0.6% | +1.7% | ||
| Neutral | 398 | +0.1% | +0.3% | ||
| Distribution | 27 | −0.9% | +0.6% | ||
| Selling | 1 | Too few readings yet | |||
Average VRTX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the VRTX price, zone by zone.Track VRTX in Gekko
Is Vertex Pharmaceuticals stock overvalued? Gekko Fair Value
Vertex Pharmaceuticals trades 9.7% above Gekko Fair Value of $463.32, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Vertex Pharmaceuticals shares are worth, recalculated every trading day.
$463.32
Gekko Fair Value, Sep 19, 2026
9.7% Overvalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open VRTX in Gekko
Vertex Pharmaceuticals insider and Congress trading
No open-market insider purchases were filed for Vertex Pharmaceuticals, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in VRTX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for VRTX, plotted on the chart in Gekko.Open VRTX in Gekko
Buybacks
Vertex Pharmaceuticals has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $473.8M
- As a share of market cap
- 0.37%
- Trailing four quarters
- $2.24B
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds VRTX.
0added1opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Vertex Pharmaceuticals earnings: next date and track record
Vertex Pharmaceuticals reports on Nov 2, 2026, after the close (43 days away), and beat the EPS estimate in 5 of its last 8 reports.
Next earnings report
Nov 2, 2026
Expected after the close, 43 days away
- EPS estimate
- $4.77
- Revenue estimate
- $3.41B
5 of 8reports beat the EPS estimate
±5.8%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 3, 2026 AI summary
- What they said
- Vertex reported Q2 2026 total revenue growth of 12% year-on-year, driven by its cystic fibrosis portfolio and newer products CASGEVY and JOURNAVX. Key pipeline milestones include BLA acceptance for Pove in IgAN with a November 30 PDUFA date, expanded CASGEVY labeling for ages 2-11, and cleared IND for VX-017 in Type 1 diabetes. Vertex announced acquisition of Crinetics Pharmaceuticals to establish a fifth pillar in rare endocrine diseases.
- Guidance
- Vertex expects to complete AMPLITUDE Phase III enrollment by year-end 2026 and report interim analysis results in early 2027. Proof-of-concept study results in DM1 and initial VX-828 patient data expected in second half of 2026. Crinetics acquisition expected to accelerate revenue growth and enhance long-term earnings.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 3, 2026 | $4.20 est $4.15 | $3.33B est $3.23B | +0.3% |
| May 4, 2026 | $4.47 est $4.31 | $2.99B est $2.99B | +0.1% |
| Feb 12, 2026 | $5.03 est $5.15 | $3.19B est $3.18B | +6.6% |
| Nov 3, 2025 | $4.80 est $4.58 | $3.08B est $3.06B | −0.9% |
| Aug 4, 2025 | $4.52 est $4.29 | $2.96B est $2.91B | −18.9% |
| May 5, 2025 | $4.06 est $4.25 | $2.77B est $2.86B | −10.2% |
| Feb 10, 2025 | $3.98 est $4.02 | $2.91B est $2.78B | −3.0% |
| Nov 4, 2024 | $4.38 est $4.13 | $2.77B est $2.69B | +6.1% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Vertex Pharmaceuticals stock forecast and analyst price targets
Analysts’ average 12-month price target for Vertex Pharmaceuticals is $569.19, +12.0% from the last close, from 26 firms rating the stock in the last 90 days.
$569.19consensus 12-month target, +12.0% from the last close
Now $508.34Avg $569.19
Low $350High $672
Each firm’s latest rating in the last 90 days: 26 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 16 | Scotiabank | $558 | +9.8% |
| Sep 14 | Morgan Stanley | $665 | +30.8% |
| Sep 11 | J.P. Morgan | $560 | +10.2% |
| Sep 2 | Citi | $585 | +15.1% |
| Sep 1 | Morgan Stanley | $665 | +30.8% |
+1.7%average 20-day move after past Accumulation readings
+3.5%average move over the next 20 trading days in the last 5 years
±2.2%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Vertex Pharmaceuticals seasonality: the next 20 trading days
Over the next 20 trading days from Sep 19, Vertex Pharmaceuticals averaged +3.5% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.6% | 1 of 5 |
| Next 10 trading days | −0.2% | 2 of 5 |
| Next 15 trading days | +1.2% | 3 of 5 |
| Next 20 trading days | +3.5% | 4 of 5 |
| Next 30 trading days | +4.3% | 4 of 5 |
For scale, VRTX’s typical 20-trading-day move in either direction is about 4.4%.
Vertex Pharmaceuticals market cap and key statistics
Vertex Pharmaceuticals’s market cap is $129.0B, with a P/E ratio of 29.9 and revenue of $12.59B over the last twelve months.
Valuation
- Market cap
- $129.0B
- P/E ratio
- 29.9
- Forward P/E
- 24
- EPS, TTM
- $17.30
- Gekko Fair Value
- $463.32
Trading
- Volume
- 2.42M
- Avg volume, 20 days
- 969,865
- 52-week high
- $560.25
- 52-week low
- $374.17
- Shares outstanding
- 253.3M
Financials
- Revenue, TTM
- $12.59B
- Profit margin
- 35%
- Return on equity
- 23.5%
- Quarterly earnings growth, YoY
- +8.0%
Risk and income
- Beta
- 0.32
- Typical daily move
- ±2.2%
- Typical 20-day move
- ±4.4%
Vertex Pharmaceuticals stock news this week
Coverage of Vertex Pharmaceuticals this week reads positive: 2 positive, 2 neutral and 1 negative headlines.
- Vertex Pharmaceuticals stock gains on higher 2026 guidanceAD HOC NEWS, Sep 19
- Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's WhyZacks Investment Research, Sep 18
- Nykredit A S Takes Position in Vertex Pharmaceuticals Incorporated $VRTXDefense World, Sep 18
- Baird Financial Group Inc. Has $2.05 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTXDefense World, Sep 18
- Engineers Gate Manager LP Cuts Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTXDefense World, Sep 17
- Amgen vs. Vertex Pharmaceuticals: Value Stability vs. High-Growth Biotech Investment PlaysNAI500, Sep 15
Vertex Pharmaceuticals peers
Vertex Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Accumulation | 15.7% above |
| JNJJohnson & Johnson | Neutral | 2.7% below |
| ABBVAbbVie | Neutral | 22.6% above |
| MRKMerck | Neutral | 7.3% below |
| AZNAstraZeneca | Neutral | 41.0% below |
| PFEPfizer | Neutral | 9.8% below |
A peer links to its own page where one exists.
Vertex Pharmaceuticals stock FAQ
What is Vertex Pharmaceuticals’s market cap?
Vertex Pharmaceuticals’s market cap is $129.0B at the Sep 18, 2026 close of $508.34, with 253.3M shares outstanding. The shares trade on a P/E ratio of 29.9.
What is the Vertex Pharmaceuticals stock forecast?
The consensus analyst 12-month price target for Vertex Pharmaceuticals is $569.19, +12.0% from the last close. Of the 26 firms that rated the stock in the last 90 days, 21 rate it a buy, 4 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
Is Vertex Pharmaceuticals stock overvalued or undervalued?
On Gekko’s estimate Vertex Pharmaceuticals is overvalued: the Sep 18, 2026 close of $508.34 is 9.7% above Gekko Fair Value of $463.32. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Vertex Pharmaceuticals report earnings next?
Vertex Pharmaceuticals is expected to report on Nov 2, 2026, after the market closes (43 days away). Analysts expect earnings of $4.77 per share on revenue of $3.41B. Vertex Pharmaceuticals beat the earnings estimate in 5 of its last 8 reports, moving 5.8% on average across the report.
What is Vertex Pharmaceuticals’s 52-week high and low?
Vertex Pharmaceuticals’s 52-week high is $560.25 and its 52-week low is $374.17; it closed at $508.34 on Sep 18, 2026, +31.3% over the past year.
Is Vertex Pharmaceuticals stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, earnings risk and seasonality), 1 as mixed (trend) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.
How this page works
Prices and signals update after every US market close; the GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Vertex Pharmaceuticals the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,349 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.